Amarantus is very good at foreshadowing what's to come if you read and re-read their prs and blogs.

Oct. 27th, 2014 - "We believe wholeheartedly in LymPro, and want to ensure that it receives the necessary management focus and commercialization expertise for it to become the gold standard for Alzheimer’s diagnosis. We expect to have updates on this initiative in the near-term."

This indicates 1 of 4 things - either they are adding additional expertise in-house, partnership, spin off, or sell off of Lympro. The 2nd and the 4th option would ensure expertise. If they want management to focus on therapeutics, this would make sense.